Nourianz is owned by Kyowa Kirin.
Nourianz contains Istradefylline.
Nourianz has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Nourianz are:
Nourianz was authorised for market use on 27 August, 2019.
Nourianz is available in tablet;oral dosage forms.
Nourianz can be used as a method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives said l-dopa therapy.
Drug patent challenges can be filed against Nourianz from 2023-08-28.
The generics of Nourianz are possible to be released after 05 September, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7541363||KYOWA KIRIN||Microcrystal|| |
(1 year, 7 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7727994||KYOWA KIRIN||Methods of treating patients suffering from movement disorders|| |
(2 months ago)
|US7727993||KYOWA KIRIN||Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy|| |
(2 months ago)
|US8318201||KYOWA KIRIN||Method of stabilizing diarylvinylene compound|| |
(4 years from now)
|New Chemical Entity Exclusivity (NCE)||Aug 27, 2024|
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 2023-08-28
Market Authorisation Date: 27 August, 2019
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic